Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis

Published:2015-03-13 Issue:10 Volume:22 Page:842-849
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Mozessohn L.¹,Chan K. K. W.²,Feld J. J.³,Hicks L. K.¹

Affiliation:

1. Division of Hematology/Oncology; St. Michael's Hospital; Toronto ON Canada

2. Division of Hematology/Oncology; Sunnybrook Odette Cancer Centre; Toronto ON Canada

3. Toronto Centre for Liver Disease; Toronto Western Hospital Liver Centre; Toronto ON Canada

Funder

Gilead

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12402/fullpdf

Reference51 articles.

1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

2. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma;Marcus;J Clin Oncol,2008

3. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis;Schulz;J Natl Cancer Inst,2007

4. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis;Edwards;N Engl J Med,2004

5. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum,2006

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16

2. Managing infectious challenges in the age of molecular‐targeted therapies for adult hematological malignancies;Transplant Infectious Disease;2024-05-02

3. Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies;Internal Medicine Journal;2023-12-08

4. Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study;BMC Health Services Research;2023-12-05

5. Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients;British Journal of Haematology;2023-10-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3